Home»Exposition»Interim analysis from EMPRISE real-world study shows Jardiance® decreased risk of hospitalization for heart failure compared with DPP-4 inhibitors and GLP-1 receptor agonists

Interim analysis from EMPRISE real-world study shows Jardiance® decreased risk of hospitalization for heart failure compared with DPP-4 inhibitors and GLP-1 receptor agonists

0
Shares
Pinterest Google+
Interim analysis from EMPRISE real-world study shows Jardiance® decreased risk of hospitalization for heart failure compared with DPP-4 inhibitors and GLP-1 receptor agonists

RIDGEFIELD, Conn. and INDIANAPOLIS, Nov. 17, 2019 /PRNewswire/ — A new interim analysis of three-year data from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) real-world study on effectiveness shows that Jardiance® (empagliflozin) was associated with a decreased risk of…

Previous post

Novartis PARAGON-HF analyses suggest Entresto® benefit beyond HFrEF

Next post

WeChat Pay Wins the People's Choice for the Harnessing the Winds of Change Award at the London Business School Real Innovation Awards 2019